What is Claude Nicaise’s Sarepta (SRPT) share ownership after this Form 4?

Following the RSU grant, Claude Nicaise directly holds 48,407 shares of Sarepta common stock. This figure reflects his position immediately after the reported acquisition and helps show the scale of the grant relative to his total direct holdings.

Director at Sarepta (NASDAQ: SRPT) receives 16,875 RSUs grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nicaise Claude reported acquisition or exercise transactions in this Form 4 filing.

Sarepta Therapeutics director Claude Nicaise received a grant of 16,875 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost per share and increase his directly held position to 48,407 shares of common stock.

Each RSU represents the right to receive one share of Sarepta common stock. The RSUs will vest on the earlier of one year from the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting, aligning vesting with the company’s annual meeting cycle.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nicaise Claude

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,875	$0.00	--

Holdings After Transaction: Common Stock — 48,407 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 16,875 shares Grant price per share: $0.00 per share Shares held after grant: 48,407 shares +1 more

4 metrics

RSU grant size 16,875 shares Restricted stock units granted to director Claude Nicaise

Grant price per share $0.00 per share Stated transaction price for RSU grant

Shares held after grant 48,407 shares Total direct Sarepta common shares following transaction

Vesting trigger Earlier of one year or next annual meeting RSUs vest on earlier of one-year anniversary or next qualifying stockholders’ meeting

Key Terms

restricted stock units ("RSUs"), vest, annual meeting of stockholders

3 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 08:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicaise Claude

(Last)

(First)

(Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		A		16,875	A	⁽¹⁾	48,407	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) disclose for Claude Nicaise?

Sarepta disclosed that director Claude Nicaise received a grant of 16,875 restricted stock units, each representing one share of common stock. The award was reported as a Form 4 transaction and increased his directly held position to 48,407 shares after the grant.

How many Sarepta (SRPT) shares were granted to Claude Nicaise and at what price?

Claude Nicaise was granted 16,875 shares of Sarepta common stock in the form of RSUs at a stated price of $0.00 per share. This reflects an equity compensation award, not an open-market share purchase, and was reported as a grant or award acquisition.

When do Claude Nicaise’s new Sarepta (SRPT) RSUs vest?

The RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholders’ meeting that occurs at least 50 weeks after the prior year’s meeting. This structure ties vesting to Sarepta’s annual governance calendar.

Is Claude Nicaise’s Sarepta (SRPT) RSU grant an open-market purchase or compensation?

The transaction is a compensation-related RSU grant, not an open-market share purchase. It was reported with transaction code “A” for a grant, award, or other acquisition, with a transaction price of $0.00 per share as typical for equity awards.